RICARDO WAKSMAN
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer(2020) D'ANDREA, David; SORIA, Francesco; ABUFARAJ, Mohammad; PONES, Mario; GONTERO, Paolo; MACHADO, Andre T.; WAKSMAN, Ricardo; ENIKEEV, Dmitry V.; GLYBOCHKO, Petr V.; ADONIAS, Sanarelly Pires; NAHAS, William Carlos; SHARIAT, Shahrokh F.; CHADE, Daher C.We compared the oncologic outcomes of patients treated with bacillus Calmette-Guerin (BCG)-Tice versus BCG-Moreau for non-muscle-invasive bladder cancer using inverse-probability survival analyses and found no significant difference in recurrence- and progression-free survival between strains. However, the use of maintenance cycles was significantly associated with improved recurrence- and progression-free survival. Prospective designed trials are required to confirm these findings in light of the BCG shortage. Background: The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guerin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). Materials and Methods: We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic centers. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and Cox proportional hazards regression analyses were used to compare recurrence-free (RFS) and progression-free survival (PFS) of patients in the 2 treatment groups. In addition, we performed exploratory analyses of treatment effect according to the receipt of adequate BCG treatment, high-risk disease, age, gender, smoking status, pathologic stage, and pathologic grade. Results: A total of 321 (48.6%) patients were treated with BCG-Tice and 339 (51.4%) with BCG-Moreau. IPTW-adjusted Cox proportional hazard regression analysis did not show a difference in RFS (hazard ratio, 0.88; 95% confidence interval, 0.56-1.38; P = .58) or PFS (hazard ratio, 0.55; 95% confidence interval, 0.25-1.21, P = .14) between BCG-Tice and BCG-Moreau. On subgroup analyses, we could not identify an association of BCG strain with outcomes. Conclusions: There was no difference in RFS and PFS between BCG-Tice and BCG-Moreau strains in the adjuvant treatment of NMIBC. However, we confirmed the importance of maintenance therapy for achieving a sustainable response in patients with intermediate- and high-risk NMIBC.
- Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer.(2017) CHADE, Daher Cezar; MACHADO, Andre; WAKSMAN, Ricardo; GARCIA, Guilherme; ESTEVES, Paulo; ADONIAS, Sanarelly; BOTELHO, Luis; CORDEIRO, Mauricio; MURTA, Claudio; RIBEIRO-FILHO, Leopoldo; SARKIS, Alvaro; BASTOS, Diogo Assed; DZIK, Carlos; SROUGI, Miguel; NAHAS, William Carlos
- Pneumomediastinum complicating COVID-19: a case series(2021) DAMOUS, Sergio Henrique Bastos; SANTOS JUNIOR, Jones Pessoa dos; PEZZANO, alvaro Vicente Alvarez; CHAMS, Mohamad Abdul Majid; HARITOV, Nathaly; WAKSMAN, Ricardo; LIMA, Helber Vidal Gadelha; MIRANDA, Jocielle dos Santos; RASSLAN, Roberto; UTIYAMA, Edivaldo MassazoBackground Pneumomediastinum is a rare complication of COVID-19 pneumonia, which may or may not be associated with invasive ventilatory support. Therefore, the report and findings associated with its evolution can be of great contribution in the management of this unknown disease. Case presentation Here, we present a series of four patients with severe pneumomediastinum requiring intensive care unit. These patients developed pneumomediastinum before or during orotracheal intubation (OTI) or without OTI. The four patients were three men and one woman with a mean age of 60.5 years (48-74 years). No patients had a known history of lung disease or traumatic events, except for one patient who had a history of smoking, but who was without parenchymal disease. All intubations were performed without complications. No cases of pneumomediastinum occurred after tracheostomy, and none of the patients had tomographic or bronchoscopic evidence of tracheal injury. Although the pneumomediastinum observed in our cases was apparently not related to a violation of the aerodigestive track, this complication was associated with a worse prognosis. Conclusion Pneumomediastinum is a rare complication of COVID-19 pneumonia, and the most likely etiopathogenesis is severe pulmonary involvement, which may or may not be associated with invasive ventilatory support. Future studies with a greater number of cases should elucidate the relationship of pneumomediastinum to a probable prognostic factor.
conferenceObject BLOOD-BASED BIOMARKERS AS PREDICTORS OF ONCOLOGIC OUTCOMES FOR NON-MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA(2017) CHADE, Daher; MACHADO, Andre; WAKSMAN, Ricardo; GARCIA, Guilherme; ESTEVES, Paulo; ADONIAS, Sanarelly; AREAS, Flavio; BOTELHO, Luis; CORDEIRO, Mauricio; MURTA, Claudio; RIBEIRO-FILHO, Leopoldo; SARKIS, Alvaro; SHARIAT, Shahrokh; BASTOS, Diogo; DZIK, Carlos; SROUGI, Miguel; NAHAS, William